{"schema_version":"secwatch.filing_event.v1","accession":"0001810560-25-000006","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2025-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.072983+00:00","generated_at":"2026-05-17T07:20:20.623952+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Revelation Biosciences PRIME Phase 1b CKD study hits endpoints; Gemini reduces inflammation in high-background patients","bullets":["Gemini met primary safety endpoint; well-tolerated at target dose with only mild Grade I events.","In patients with high background inflammation (≈50%), Gemini significantly reduced IL-1β, TNF-α, IL-6, IL-10, IL-1RA vs placebo (p<0.01) through 7 days.","Gemini restored normal cellular response to LPS/HMGB1 stimuli in high-background PBMCs, reversing immunoparalysis (IL-1β p<0.0001).","Company scheduled End of Phase 1 meeting with FDA later in 2025 to discuss advancement.","40 patients enrolled across 5 dose cohorts in 3 US clinics; data webcast on Sept 10, 2025 at 8:30 AM ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001810560-25-000006","json":"https://secwatch.observer/filing/0001810560-25-000006.json","markdown":"https://secwatch.observer/filing/0001810560-25-000006.md","text":"https://secwatch.observer/filing/0001810560-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000181056025000006/0001810560-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000181056025000006/revb-20250909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:20:20.623952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}